An­oth­er Eylea com­peti­tor pre­pares to en­ter the ring fol­low­ing pos­i­tive PhI­II read­out

Re­gen­eron may soon be star­ing down an­oth­er com­peti­tor to its block­buster Eylea. San­doz’s biosim­i­lar can­di­date afliber­cept proved equiv­a­lent to the brand-name eye drug in a Phase III tri­al, San­doz an­nounced Tues­day.

The study pit­ted the biosim­i­lar against Eylea in pa­tients with neo­vas­cu­lar age-re­lat­ed mac­u­lar de­gen­er­a­tion, an eye con­di­tion that can lead to vi­sion loss. Ac­cord­ing to San­doz, the biosim­i­lar showed “ther­a­peu­tic equiv­a­lence” to Eylea in mean change of best cor­rect­ed vi­su­al acu­ity over eight weeks, and across safe­ty, im­muno­genic­i­ty and phar­ma­co­ki­net­ics. The re­sults will al­low the No­var­tis gener­ics unit to file for ap­proval in the US and EU “in the com­ing months.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER